2. Search Result
Search Result
Results for "

C57B/L mice

" in MedChemExpress (MCE) Product Catalog:

5662

Inhibitors & Agonists

1

Screening Libraries

37

Fluorescent Dye

300

Biochemical Assay Reagents

631

Peptides

1

MCE Kits

93

Inhibitory Antibodies

951

Natural
Products

696

Recombinant Proteins

634

Isotope-Labeled Compounds

298

Antibodies

113

Click Chemistry

528

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1170
    N-terminally acetylated Leu-enkephalin

    Ac-L-Tyr-Gly-Gly-L-Phe-D-Leu-COOH

    		 Opioid Receptor Neurological Disease
    N-terminally acetylated Leu-enkephalin is the N-terminally acetylated form of Leu-enkephalin. Leu-enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.
    N-terminally acetylated Leu-enkephalin
  • HY-121834
    RNase L-IN-2

    		DNA/RNA Synthesis Others
    RNase L-IN-2 (compound 2) is an activtor of RNase L with EC50 value of 22 μM .
    RNase L-IN-2
  • HY-P1173
    L803-mts

    Myristoylated L 803; GSK-3β Inhibitor XIII

    		 GSK-3 Amyloid-β Neurological Disease
    L803-mts (Myristoylated L 803) is a selective and substrate-competitive GSK-3 peptide inhibitor (IC50: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test .
    L803-mts
  • HY-112234
    L-Sepiapterin

    Sepiapterin

    		 Endogenous Metabolite Cancer
    L-Sepiapterin (Sepiapterin) is a precursor of the endothelial nitric oxide synthase (eNOS) cofactor tetrahydrobiopterin (BH4). L-Sepiapterin improves endothelial dysfunction in small mesenteric arteries from db/db mice, and induces angiogenesis. L-Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 S6K-dependent VEGFR-2 expression .
    L-Sepiapterin
  • HY-P991208
    Flt-3L-Ig (hum/hum)

    human Flt3L; hFlt3L

    		 FLT3 Inflammation/Immunology
    Flt-3L-Ig (hum/hum) (hFlt3L) is a Flt3 activator. Flt-3L-Ig (hum/hum) enhances OKT3-induced inflammatory cytokine release from myeloid and dendritic cells in BRGSF-CBC mice, as well as the number and distribution of human immune cells, exhibiting cytokine release syndrome (CRS) .
    Flt-3L-Ig (hum/hum)
  • HY-158812
    Eicosapentaenoyl-L-carnitine chloride

    		Drug Derivative Metabolic Disease
    Eicosapentaenoyl-L-carnitine chloride is a long-chain acylcarnitine composed of Eicosapentaenoic Acid (HY-B0660) and L-Carnitine (HY-B0399). The levels of Eicosapentaenoyl-L-carnitine chloride are increased in the eyes of mice fed a diet high in n-3/n-6 polyunsaturated fatty acids (PUFAs) in a mouse model of myopia induced by out-of-focus lenses .
    Eicosapentaenoyl-L-carnitine chloride
  • HY-137392
    Cathepsin L-IN-4

    1-Naphthalenesulfonyl-Ile-Trp-CHO

    		 Cathepsin Others
    Cathepsin L-IN-4 is an inhibitor of cathepsin L with IC50 at nanomolar concentrations .
    Cathepsin L-IN-4
  • HY-163389
    Mpro/Cathepsin L-IN-1

    		SARS-CoV Cathepsin Infection
    Mpro/Cathepsin L-IN-1 (Compound 4d) is a SARS-CoV-2 M pro/hCatL inhibitor, with Kis of 5.54 μM and 0.701 μM respectively .
    Mpro/Cathepsin L-IN-1
  • HY-173257
    Cath-L-dBET1

    		Epigenetic Reader Domain PROTACs Cancer
    Cath-L-dBET1 is a PROTAC degrader targeting BRD4. Cath-L-dBET1 has an IC50 value of 2.8 μM in MDA-MB-231 cells. Cath-L-dBET1 can be activated by cathepsin L (Cath-L) and recruit the E3 ubiquitin ligase and degrade BRD4 through ubiquitin-proteasome system. Hyp-dBET1 can be used for anti-tumor study .
    Cath-L-dBET1
  • HY-135141
    Tetrahydroechinocandin B

    L-687901

    		 Fungal Infection
    Tetrahydroechinocandin B (L 687,901) is a potent antifungal agent. Tetrahydroechinocandin B inhibits 1,3-beta-D-glucan synthesis with an IC50 of 0.85 μg/mL .
    Tetrahydroechinocandin B
  • HY-122323
    L-Leucyl-L-arginine

    Leucylarginine

    		 Amino Acid Derivatives Others
    L-Leucyl-L-arginine (Leucylarginine) is a compound that inhibits the analgesic effect of systemically administered L-arginine in a carrageenan-induced hyperalgesia model in mice when administered intracerebroventricularly.
    L-Leucyl-L-arginine
  • HY-14608R
    L-Glutamic acid (Standard)

    		Endogenous Metabolite iGluR Ferroptosis Apoptosis Neurological Disease
    L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC50 & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus .
    L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma .
    In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice .
    L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .
    L-Glutamic acid (Standard)
  • HY-169171
    Cathepsin L-IN-5

    		Cathepsin Infection
    Cathepsin L-IN-5 (D6-3) is a potent Cathepsin L (CatL) inhibitor with an IC50 of 0.27 nM. Cathepsin L-IN-5 effectively blocks the CatL function and substantially hinders the entry of the SARS-CoV-2 pseudovirus to cells by inhibiting the cleavage of the spike protein. Cathepsin L-IN-5 can be utilized in SARS-CoV-2 research .
    Cathepsin L-IN-5
  • HY-168457
    RNase L ligand 2

    		SARS-CoV Others
    RNase L ligand 2 (compound 6) is the Rnase L ligand part of RNAse L RIBOTAC (HY-168455), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNase L ligand 2 can be used in the synthesis of RIBOTAC .
    RNase L ligand 2
  • HY-115889
    L-NAPNA

    		NO Synthase Neurological Disease
    L-NAPNA is a nitric oxide synthase (NOS) inhibitor with an IC50 of 1.4 μM. L-NAPNA exhibits analgesic effects by inhibiting formalin-induced paw licking behavior in mice (ED50 of 57.2 mg/kg) and suppressing acetic acid-induced abdominal writhing in mice (ED50 of 25 mg/kg). L-NAPNA can be used in research related to central nervous system diseases .
    L-NAPNA
  • HY-W014233
    L-Histidinol dihydrochloride

    		Endogenous Metabolite Aminoacyl-tRNA Synthetase Cancer
    L-Histidinol dihydrochloride is an orally active histidyl-tRNA synthetase inhibitor. L-Histidinol dihydrochloride interferes with the initiation stage of protein synthesis, thus affecting cell proliferation and metabolism. L-Histidinol dihydrochloride has the effect of modulating the sensitivity of tumor cells to chemotherapeutic agents. L-Histidinol dihydrochloride reduces the toxicity of certain chemotherapeutic agents to normal tissues and enhance the sensitivity of tumor cells to chemotherapeutic agents .
    L-Histidinol dihydrochloride
  • HY-N15180
    Corynantheidine

    (-)-Corynantheidine

    		 Opioid Receptor Neurological Disease
    Corynantheidine ((-)-Corynantheidine) is a mu-opioid receptor (MOR) partial agonist that shows MOR-dependent analgesic effects in mice .
    Corynantheidine
  • HY-107734
    L 152804

    		Neuropeptide Y Receptor Metabolic Disease Endocrinology
    L 152804 is an orally active and selective neuropeptide Y Y5 receptor (NPY5-R) antagonist, with a Ki of 26 nM for hY5. L 152804 causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure .
    L 152804
  • HY-145729
    Danvatirsen

    AZD9150

    		 STAT Apoptosis Cancer
    Danvatirsen is an antisense oligonucleotide targeting STAT3 with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth.
    Danvatirsen
  • HY-147252
    Bezeparsen

    		PCSK9 Metabolic Disease
    Bezeparsen is a PCSK9 synthesis inhibitor .
    Bezeparsen
  • HY-137440A
    Firazorexton hydrate

    TAK-994

    		 Orexin Receptor (OX Receptor) ERK Neurological Disease
    Firazorexton hydrate (TAK-994) is an orally active and brain-penetrant orexin type 2 receptor (OX2R) selective agonist. Firazorexton hydrate can promote wakefulness and has the potential to improve narcolepsy-like symptoms in mice .
    Firazorexton hydrate
  • HY-120872
    AJS1669 free acid

    		Glycosyltransferase Metabolic Disease
    AJS1669 free acid is a potent and orally available glycogen synthase (GS) activator. AJS1669 improves glucose metabolism and reduces body fat mass in mice[1].
    AJS1669 free acid
  • HY-N10346A
    Gluconapin

    		Endogenous Metabolite Cancer
    Gluconapin is a precursor of sulforaphane, a potent anticancer isothiocyanate. Gluconapin reduces the increase in plasma triglycerides induced by corn oil in mice .
    Gluconapin
  • HY-132600
    RG-101

    Temavirsen

    		 MicroRNA HCV Infection
    RG-101 is a hepatocyte targeted N-acetylgalactosamine conjugated oligonucleotide that antagonises miR-122. miR-122 is an important host factor for hepatitis C virus (HCV) replication .
    RG-101
  • HY-N0469R
    L-Lysine (Standard)

    		Endogenous Metabolite Virus Protease HSV Infection Metabolic Disease Inflammation/Immunology
    L-Lysine (Standard) is the analytical standard of L-Lysine. This product is intended for research and analytical applications. L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation . IC50 & Target:L-lysine (150 mg/kg) promotes, but not initiates, bladder cancer. The administration of L-lysine to rats submitted to colovesical cystoplasty accelerates the development of transitional metaplasia of the intestinal epithelium .
    L-lysine (10 mg/kg) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity . In Vivo:L-lysine (10?mg/kg, p.o., pre-treated or post-treated, administration duration 15 days) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity in acute pancreatitis mice model . L-lysine (5 or 10?mg/kg, p.o., 45 days) ameliorates sepsis-induced acute lung injury in a lipopolysaccharide (HY-D1056)-induced mouse model .
    L-Lysine (Standard)
  • HY-145725A
    Baliforsen

    ISIS 598769; IONIS 598769; BIIB 065; ISIS-DMPK-2.5Rx

    		 Ser/Thr Kinase Others
    Baliforsen is an antisense oligonucleotide (16 nucleotides) designed to target myotonic dystrophy protein kinase (DMPK) mRNA and research myotonic dystrophy.
    Baliforsen
  • HY-101404A
    L-Homocysteine thiolactone hydrochloride

    		Amino Acid Derivatives Cardiovascular Disease Inflammation/Immunology
    L-Homocysteine thiolactone hydrochloride is an intramolecular thioester of Homocysteine. Homocysteine thiolactone hydrochloride prevents translational incorporation of homocysteine into proteins. L-Homocysteine thiolactone hydrochloride can induce elevated HHcy (hyperhomocysteinemia) in mice .
    L-Homocysteine thiolactone hydrochloride
  • HY-113878
    12-OAHSA

    		Endogenous Metabolite Metabolic Disease
    12-OAHSA is a component of olive oil. 12-OAHSA has oral activity, and improves glucose homeostasis in insulin resistant obese mice .
    12-OAHSA
  • HY-138842
    DDN

    		Insulin Receptor Akt ERK Metabolic Disease
    DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .
    DDN
  • HY-137440
    Firazorexton

    TAK-994 free base

    		 Orexin Receptor (OX Receptor) ERK Neurological Disease
    Firazorexton (TAK-994 free base) is an orally active and brain-penetrant orexin type 2 receptor (OX2R) selective agonist. Firazorexton (TAK-994 free base) can promote wakefulness and has the potential to improve narcolepsy-like symptoms in mice .
    Firazorexton
  • HY-162396
    P-gp inhibitor 21

    		P-glycoprotein Cancer
    P-gp inhibitor 21 (Compound 56) is an inhibitor for P-glycoprotein (P-gp) transport, which reverses P-gp-mediated multidrug resistance (MDR) and exhibits antitumor efficacy in mice without significant cytotoxicity .
    P-gp inhibitor 21
  • HY-153617
    FOXO1-IN-3

    		FOXO Metabolic Disease
    FOXO1-IN-3 is a highly-selective and orally active FOXO1 inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain .
    FOXO1-IN-3
  • HY-126426
    CBHcy

    		DNA Methyltransferase Cardiovascular Disease
    CBHcy is an inhibitor for betaine-homocysteine S-methyltransferase (BGMT), with an IC50 of 0.09 μM. CBHcy upregulates the plasma total homocysteine and causes transient hyperhomocysteinemia in mice model .
    CBHcy
  • HY-145525
    Linoleoyl-L-carnitine chloride

    CAR 18:2; C18:2 Carnitine; L-Carnitine linoleoyl ester

    		 Endogenous Metabolite Others
    Linoleoyl-L-carnitine is a naturally occurring long-chain acylcarnitine. Hepatic levels of linoleoyl-L-carnitine are increased following high-dose (200 mg/kg) administration of Isoniazid (Item No. 20378) in mice.
    Linoleoyl-L-carnitine chloride
  • HY-W010042
    L-Glucose

    L-(-)-Glucose

    		 Fluorescent Dye Metabolic Disease Cancer
    L-Glucose (L-(-)-Glucose) is a stereoisomer of D-Glucose (HY-B0389), which does not readily enter the brain. L-Glucose can promote food intake. L-glucose is combined with a fluorescence detector to produce a fluorescent probe that can be used to visualize and characterize cancer cells. L-Glucose also can be used in the research to enhance memory in mice .
    L-Glucose
  • HY-P3134
    CPN-267

    		Neuromedin U Receptor (NMUR) Metabolic Disease
    CPN-267 (compound 7b) is a selective neuromedin U receptor 1 (NMUR1) agonist with the EC50 of 0.25 nM. CPN-267 suppresses body weight gain in mice and can be used for study of obesity .
    CPN-267
  • HY-129661
    AH 7959

    		Opioid Receptor Neurological Disease
    AH 7959 is an orally active N-substituted cyclohexyl methyl benzamide compound that has analgesic effects, the oral and subcutaneous ED50 of AH 7959 in mice is greater than 100 mg/kg .
    AH 7959
  • HY-P6053
    KK-103

    		Opioid Receptor Neurological Disease
    KK-103 is a precursor of leucine-enkephalin (Leu-ENK) overcomes high proteolytic instability of Leu-ENK via markedly increased plasma stability in mice that has antinociceptive effect .
    KK-103
  • HY-108559
    L-161982

    		Prostaglandin Receptor Inflammation/Immunology
    L-161982 is a selective EP4 receptor antagonist. L-161982 completely blocks PGE2-induced ERK phosphorylation and cell proliferation of HCA-7 cells. L-161982 alleviates collagen-induced arthritis in mice .
    L-161982
  • HY-116597
    L-783483

    F3MethylAA

    		 PPAR Inflammation/Immunology
    L-783483 (F3MethylAA) is an agonist for PPARδ. L-783483 ameliorates Carrageenan (HY-125474)-induced paw edema in mice .
    L-783483
  • HY-163387
    CHI3L1-IN-1

    		Glycosidase Potassium Channel Inflammation/Immunology Cancer
    CHI3L1-IN-1 (Compound 30) is an inhibitor for Chitinase-3-like protein 1 (CHI3L1) (YKL-40) with IC50 of 50 nM. CHI3L1-IN-1 inhibits hERG channel with an IC50 of 2.3 μM .
    CHI3L1-IN-1
  • HY-168365
    (±)-Pellotine hydrochloride

    		Drug Isomer Neurological Disease
    (±)-Pellotine hydrochloride (Compound 2) is an alkaloid, which is found in L. diffusa and L. fricii. (±)-Pellotine hydrochloride decreases locomotor activity and the amount of rapid eye movement (REM) sleep in mice .
    (±)-Pellotine hydrochloride
  • HY-169421
    Nav1.7-IN-18

    		Sodium Channel Cancer
    Nav1.7-IN-18 (Compound 31) is a Nav1.7 inhibitor with a Ki value of 4.9 nM and an IC50 of 13 nM, showing analgesic effects in transgenic mice with inherited erythromelalgia (IEM) .
    Nav1.7-IN-18
  • HY-108497
    L-803087

    		Somatostatin Receptor Neurological Disease Cancer
    L-803087 is a potent and selective somatostatin sst4 receptor agonist with a Ki of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice .
    L-803087
  • HY-N15182
    4-Trehalosamine

    		Bacterial Drug Derivative Infection
    4-Trehalosamine is a derivative of trehalose with weak antibacterial activity. 4-Trehalosamine shows no toxic effects when injected intravenously into mice at a dose of 625 mg/kg .
    4-Trehalosamine
  • HY-147406
    Tonlamarsen

    ION-904

    		 Endogenous Metabolite Cardiovascular Disease
    Tonlamarsen is a angiotensinogen synthesis reducer, with antihypertensive activity .
    Tonlamarsen
  • HY-110197
    6bK TFA
    1 Publications Verification

    		 Insulin Receptor Metabolic Disease
    6bK TFA is a potent and selective insulin degrading enzyme (IDE) inhibitor with an IC50 value of 50 nM. 6bK TFA increases circulating insulin in high-fat-fed mice. Acute administration of 6bK TFA enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice .
    6bK TFA
  • HY-162683
    (S)-PHA533533

    		CDK Neurological Disease Cancer
    (S)-PHA533533 is a cyclin-dependent kinase 2 (CDK2) inhibitor. (S)-PHA533533 shows anti-tumor activity and can induce widespread neuronal UBE3A expression in angelman syndrome model mice .
    (S)-PHA533533
  • HY-13859
    Clevudine

    L-FMAU

    		 HBV DNA/RNA Synthesis Orthopoxvirus Infection
    Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent anti-HBV activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase. Clevudine is active against cowpox virus respiratory infection in mice .
    Clevudine
  • HY-W016145
    L-Glutamic acid monosodium (hydrate)

    		Apoptosis Metabolic Disease Cancer
    L-Glutamic acid monosodium hydrate is a nutritional additive and flavoring agent. L-Glutamic acid monosodium hydrate can reduce obesity and induce metabolic disorders associated with oxidative stress. L-Glutamic acid monosodium hydrate induces oxidative stress,DNA damage and apoptosis in the liver and brain tissues of mice .
    L-Glutamic acid monosodium (hydrate)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: